在泌尿外科手术室开展创新型临床药学服务:卡塔尔的一项新举措。

IF 3.3 Q1 HEALTH POLICY & SERVICES
Journal of Pharmaceutical Policy and Practice Pub Date : 2024-09-23 eCollection Date: 2024-01-01 DOI:10.1080/20523211.2024.2401478
Lina Naseralallah, Somaya Koraysh, Nour Isleem, Afif Ahmed, Moza Al Hail
{"title":"在泌尿外科手术室开展创新型临床药学服务:卡塔尔的一项新举措。","authors":"Lina Naseralallah, Somaya Koraysh, Nour Isleem, Afif Ahmed, Moza Al Hail","doi":"10.1080/20523211.2024.2401478","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To provide an insight into the role of a clinical pharmacy initiative in a surgical urology unit through evaluating the nature, significance, associated medications, and acceptance rate of pharmacist interventions.</p><p><strong>Methods: </strong>A cross-sectional study was carried out at the Ambulatory Care Center (ACC), Doha, Qatar. Data related to clinical pharmacist interventions and associated rationale were classified according to the nature of the intervention using an adapted classification system. The assessment of the severity followed the National Patient Safety Agency (NPSA) Risk Matrix. Linear regression, Kruskal-Wallis, and post-hoc analyses were performed to determine the association between patient-related and medication-related characteristics on pharmacist interventions.</p><p><strong>Results: </strong>A total of 3284 interventions (on 1486 patients) were analysed. Most patients (<i>n</i> = 1105; 74.4%) had 1-2 interventions. Age and gender showed a positive linear correlation with the number of interventions per patient (<i>p</i> < 0.01). Majority of interventions were related to pharmacological strategy (<i>n</i> = 1858; 56.6%) and quantity of drug (<i>n</i> = 821; 25%). Additional drug therapy (<i>n</i> = 748; 22.78%) was the most common subcategory followed by optimum dose/frequency (<i>n</i> = 691; 21.04%) and discontinuation of medications (<i>n</i> = 352, 10.72%). Anti-infectives were the most identified drug category (<i>n</i> = 798, 55.1%). Most interventions (59.4%) were of moderate significance; patients with moderate interventions were found to be older compared to patients with minor interventions (<i>p</i> = 0.032). Prescribers' acceptance rate was high (>90%), with a notable increase of 6.6% from 2021 to 2023.</p><p><strong>Conclusion: </strong>This study showed that the clinical pharmacy service in the urology surgical field was a fruitful initiative. The clinical pharmacist's role has expanded to include not only therapeutic optimisation while ensuring medication safety across the continuum of perioperative care but also the identification and management of untreated health problems. The dynamic and complexity of the urology patient population challenge clinical pharmacists; however, the practice concepts remain the same as in any other clinical setting.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421156/pdf/","citationCount":"0","resultStr":"{\"title\":\"Development of an innovative clinical pharmacy service in a urology surgical unit: a new initiative from Qatar.\",\"authors\":\"Lina Naseralallah, Somaya Koraysh, Nour Isleem, Afif Ahmed, Moza Al Hail\",\"doi\":\"10.1080/20523211.2024.2401478\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To provide an insight into the role of a clinical pharmacy initiative in a surgical urology unit through evaluating the nature, significance, associated medications, and acceptance rate of pharmacist interventions.</p><p><strong>Methods: </strong>A cross-sectional study was carried out at the Ambulatory Care Center (ACC), Doha, Qatar. Data related to clinical pharmacist interventions and associated rationale were classified according to the nature of the intervention using an adapted classification system. The assessment of the severity followed the National Patient Safety Agency (NPSA) Risk Matrix. Linear regression, Kruskal-Wallis, and post-hoc analyses were performed to determine the association between patient-related and medication-related characteristics on pharmacist interventions.</p><p><strong>Results: </strong>A total of 3284 interventions (on 1486 patients) were analysed. Most patients (<i>n</i> = 1105; 74.4%) had 1-2 interventions. Age and gender showed a positive linear correlation with the number of interventions per patient (<i>p</i> < 0.01). Majority of interventions were related to pharmacological strategy (<i>n</i> = 1858; 56.6%) and quantity of drug (<i>n</i> = 821; 25%). Additional drug therapy (<i>n</i> = 748; 22.78%) was the most common subcategory followed by optimum dose/frequency (<i>n</i> = 691; 21.04%) and discontinuation of medications (<i>n</i> = 352, 10.72%). Anti-infectives were the most identified drug category (<i>n</i> = 798, 55.1%). Most interventions (59.4%) were of moderate significance; patients with moderate interventions were found to be older compared to patients with minor interventions (<i>p</i> = 0.032). Prescribers' acceptance rate was high (>90%), with a notable increase of 6.6% from 2021 to 2023.</p><p><strong>Conclusion: </strong>This study showed that the clinical pharmacy service in the urology surgical field was a fruitful initiative. The clinical pharmacist's role has expanded to include not only therapeutic optimisation while ensuring medication safety across the continuum of perioperative care but also the identification and management of untreated health problems. The dynamic and complexity of the urology patient population challenge clinical pharmacists; however, the practice concepts remain the same as in any other clinical setting.</p>\",\"PeriodicalId\":16740,\"journal\":{\"name\":\"Journal of Pharmaceutical Policy and Practice\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421156/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmaceutical Policy and Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/20523211.2024.2401478\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"HEALTH POLICY & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Policy and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20523211.2024.2401478","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

目的:通过评估药剂师干预措施的性质、意义、相关药物和接受率,深入了解临床药学措施在泌尿外科手术室中的作用:在卡塔尔多哈的非住院医疗中心(ACC)开展了一项横断面研究。与临床药剂师干预相关的数据和相关理由均根据干预的性质进行了分类,并使用了一套经过改编的分类系统。严重程度的评估遵循国家患者安全局(NPSA)的风险矩阵。通过线性回归、Kruskal-Wallis和事后分析来确定患者相关特征和药物相关特征与药剂师干预之间的关联:共分析了 3284 次干预(针对 1486 名患者)。大多数患者(n = 1105;74.4%)接受了 1-2 次干预。年龄和性别与每位患者的干预次数(p n = 1858;56.6%)和药物数量(n = 821;25%)呈正线性关系。额外药物治疗(n = 748;22.78%)是最常见的子类别,其次是最佳剂量/频率(n = 691;21.04%)和停药(n = 352,10.72%)。抗感染药物是被确认最多的药物类别(n = 798,55.1%)。大多数干预措施(59.4%)为中度干预措施;与轻度干预措施患者相比,中度干预措施患者的年龄更大(p = 0.032)。处方者的接受率很高(大于 90%),从 2021 年到 2023 年显著增加了 6.6%:本研究表明,在泌尿外科手术领域开展临床药学服务是一项卓有成效的举措。临床药剂师的作用已扩大到不仅包括优化治疗,同时确保整个围手术期护理过程中的用药安全,还包括识别和管理未经治疗的健康问题。泌尿科患者群体的动态性和复杂性对临床药剂师提出了挑战,但其实践理念与其他临床环境相同。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Development of an innovative clinical pharmacy service in a urology surgical unit: a new initiative from Qatar.

Purpose: To provide an insight into the role of a clinical pharmacy initiative in a surgical urology unit through evaluating the nature, significance, associated medications, and acceptance rate of pharmacist interventions.

Methods: A cross-sectional study was carried out at the Ambulatory Care Center (ACC), Doha, Qatar. Data related to clinical pharmacist interventions and associated rationale were classified according to the nature of the intervention using an adapted classification system. The assessment of the severity followed the National Patient Safety Agency (NPSA) Risk Matrix. Linear regression, Kruskal-Wallis, and post-hoc analyses were performed to determine the association between patient-related and medication-related characteristics on pharmacist interventions.

Results: A total of 3284 interventions (on 1486 patients) were analysed. Most patients (n = 1105; 74.4%) had 1-2 interventions. Age and gender showed a positive linear correlation with the number of interventions per patient (p < 0.01). Majority of interventions were related to pharmacological strategy (n = 1858; 56.6%) and quantity of drug (n = 821; 25%). Additional drug therapy (n = 748; 22.78%) was the most common subcategory followed by optimum dose/frequency (n = 691; 21.04%) and discontinuation of medications (n = 352, 10.72%). Anti-infectives were the most identified drug category (n = 798, 55.1%). Most interventions (59.4%) were of moderate significance; patients with moderate interventions were found to be older compared to patients with minor interventions (p = 0.032). Prescribers' acceptance rate was high (>90%), with a notable increase of 6.6% from 2021 to 2023.

Conclusion: This study showed that the clinical pharmacy service in the urology surgical field was a fruitful initiative. The clinical pharmacist's role has expanded to include not only therapeutic optimisation while ensuring medication safety across the continuum of perioperative care but also the identification and management of untreated health problems. The dynamic and complexity of the urology patient population challenge clinical pharmacists; however, the practice concepts remain the same as in any other clinical setting.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Pharmaceutical Policy and Practice
Journal of Pharmaceutical Policy and Practice Health Professions-Pharmacy
CiteScore
4.70
自引率
9.50%
发文量
81
审稿时长
14 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信